Michel Lefranc1, Leila Maria Da Roz2, Anne Balossier3, Jean Marc Thomassin4, Pierre Hugue Roche5, Jean Regis3. 1. Department of Neurosurgery, University of Picardy Jules Verne, Amiens, France. Electronic address: lefrancm@me.com. 2. Stereotactic Radiosurgery-Gamma-Unit, Aix-Marseille University, Marseille, France. 3. ENT, Hospital Timone, Aix-Marseille University, Marseille, France. 4. Department of Neurosurgery, Das Clinicas Hospital, University of Sao Paulo, Sao Paulo, Brazil. 5. Department of Neurosurgery, CHU North Hospital, Aix-Marseille University, Marseille, France.
Abstract
INTRODUCTION: Grade IV vestibular schwannoma (Koos classification) is generally considered to be an indication for microsurgical resection or combined radiosurgery-microsurgery. However, the place of Gamma Knife stereotactic surgery (GK-SRS), either as first-line treatment or when progression of residual tumor compresses the brainstem, has not been clearly evaluated. This article reports the results of a large case series of patients with grade 4 vestibular schwannoma treated by GK-SRS. MATERIAL AND METHOD: All consecutive patients with grade IV vestibular schwannoma treated by GK-SRS in our department between 1996 and 2011 with a minimum follow-up of 3 years were included in this study. RESULTS: 86 patients were treated by GK-SRS with a minimum follow-up of 3 years. Mean follow-up was 6.2 years (3-16 years). The mean age of the patients at the time of GK-SRS was 54.6 years (range: 23-84) and the sex ratio was 0.6. At the time of radiosurgery, no patient presented brainstem dysfunction prior to GK-SRS. 38 patients had functional hearing before treatment. One patient presented mild trigeminal neuralgia before GK-SRS. Tumor control with no clinical deterioration was obtained in 78 patients (90.7%). No radiation-induced brainstem or cranial nerve toxicity was observed in any of these patients. Functional hearing was maintained in 25 patients. 8 (9.3%) patients presented tumor growth and required microsurgical resection in 7 cases and ventricular shunt in 1 case. CONCLUSION: On the basis of this large series, GK-SRS appears to be a safe and effective treatment option for grade IV vestibular schwannoma for patients with no signs of brainstem dysfunction.
INTRODUCTION: Grade IV vestibular schwannoma (Koos classification) is generally considered to be an indication for microsurgical resection or combined radiosurgery-microsurgery. However, the place of Gamma Knife stereotactic surgery (GK-SRS), either as first-line treatment or when progression of residual tumor compresses the brainstem, has not been clearly evaluated. This article reports the results of a large case series of patients with grade 4 vestibular schwannoma treated by GK-SRS. MATERIAL AND METHOD: All consecutive patients with grade IV vestibular schwannoma treated by GK-SRS in our department between 1996 and 2011 with a minimum follow-up of 3 years were included in this study. RESULTS: 86 patients were treated by GK-SRS with a minimum follow-up of 3 years. Mean follow-up was 6.2 years (3-16 years). The mean age of the patients at the time of GK-SRS was 54.6 years (range: 23-84) and the sex ratio was 0.6. At the time of radiosurgery, no patient presented brainstem dysfunction prior to GK-SRS. 38 patients had functional hearing before treatment. One patient presented mild trigeminal neuralgia before GK-SRS. Tumor control with no clinical deterioration was obtained in 78 patients (90.7%). No radiation-induced brainstem or cranial nerve toxicity was observed in any of these patients. Functional hearing was maintained in 25 patients. 8 (9.3%) patients presented tumor growth and required microsurgical resection in 7 cases and ventricular shunt in 1 case. CONCLUSION: On the basis of this large series, GK-SRS appears to be a safe and effective treatment option for grade IV vestibular schwannoma for patients with no signs of brainstem dysfunction.
Authors: Chloe Dumot; Stylianos Pikis; Georgios Mantziaris; Zhiyuan Xu; Rithika Kormath Anand; Ahmed M Nabeel; Darrah Sheehan; Kimball Sheehan; Wael A Reda; Sameh R Tawadros; Khaled Abdel Karim; Amr M N El-Shehaby; Reem M Emad Eldin; Selcuk Peker; Yavuz Samanci; Tehila Kaisman-Elbaz; Herwin Speckter; Wenceslao Hernández; Julio Isidor; Manjul Tripathi; Renu Madan; Brad E Zacharia; Lekhaj C Daggubati; Nuria Martínez Moreno; Roberto Martínez Álvarez; Anne-Marie Langlois; David Mathieu; Christopher P Deibert; Vivek R Sudhakar; Christopher P Cifarelli; Denisse Arteaga Icaza; Daniel T Cifarelli; Zhishuo Wei; Ajay Niranjan; Gene H Barnett; L Dade Lunsford; Greg N Bowden; Jason P Sheehan Journal: J Neurooncol Date: 2022-09-27 Impact factor: 4.506
Authors: Scott G Soltys; Michael T Milano; Jinyu Xue; Wolfgang A Tomé; Ellen Yorke; Jason Sheehan; George X Ding; John P Kirkpatrick; Lijun Ma; Arjun Sahgal; Timothy Solberg; John Adler; Jimm Grimm; Issam El Naqa Journal: Int J Radiat Oncol Biol Phys Date: 2020-12-26 Impact factor: 8.013
Authors: Daniele Starnoni; Lorenzo Giammattei; Giulia Cossu; Michael J Link; Pierre-Hugues Roche; Ari G Chacko; Kenji Ohata; Majid Samii; Ashish Suri; Michael Bruneau; Jan F Cornelius; Luigi Cavallo; Torstein R Meling; Sebastien Froelich; Marcos Tatagiba; Albert Sufianov; Dimitrios Paraskevopoulos; Idoya Zazpe; Moncef Berhouma; Emmanuel Jouanneau; Jeroen B Verheul; Constantin Tuleasca; Mercy George; Marc Levivier; Mahmoud Messerer; Roy Thomas Daniel Journal: Acta Neurochir (Wien) Date: 2020-07-29 Impact factor: 2.216
Authors: Won Jae Lee; Jung Il Lee; Jung Won Choi; Doo Sik Kong; Do Hyun Nam; Yang Sun Cho; Hyung Jin Shin; Ho Jun Seol Journal: J Korean Med Sci Date: 2021-04-26 Impact factor: 2.153
Authors: Daniel Rueß; Lea Pöhlmann; Stefan Grau; Christina Hamisch; Mauritius Hoevels; Harald Treuer; Christian Baues; Martin Kocher; Maximillian Ruge Journal: Sci Rep Date: 2020-06-09 Impact factor: 4.379
Authors: Patrick P J H Langenhuizen; Sander H P Sebregts; Svetlana Zinger; Sieger Leenstra; Jeroen B Verheul; Peter H N de With Journal: Med Phys Date: 2020-02-18 Impact factor: 4.071
Authors: Umberto Tosi; Miguel E Tusa Lavieri; Anjile An; Omri Maayan; Sergio W Guadix; Antonio P DeRosa; Paul J Christos; Susan Pannullo; Philip E Stieg; Andrew Brandmaier; Jonathan P S Knisely; Rohan Ramakrishna Journal: Neurooncol Pract Date: 2021-02-18